Archive for the ‘Puramed Bioscience Inc. PMBS’ Category

Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar

Monday, April 6th, 2009

PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.

Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).

PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.

The share structure of the stock is also attractive with only 7,929,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.

With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.

Let us hear your thoughts below:

PuraMed Bioscience, Inc. (PMBS.OB) Targets Two Market Opportunities

Friday, April 3rd, 2009

PuraMed Bioscience, Inc., a non-prescription pharmaceutical company, believes it has identified huge and largely untapped market opportunities, and has laid out a solid plan to capture them. The company, based in Schofield, Wisconsin, was established with two specific goals in mind, representing these two OTC (over-the-counter) product opportunities.

The first objective is to rapidly build a substantial and profitable business based upon three OTC products already developed by the company founders. The products, designed for headache and insomnia relief, are each unique in their own class, and collectively target a $2 billion American market.

LipiGesic MTM is a proprietary formulation created for the acute relief of migraine headaches within minutes. LipiGesic HTM is designed to dramatically increase the speed and levels of relief of tension headaches, effective at low doses and with the fewest potential side effects. LipiGesic PMTM is a new class of OTC sleep aid containing a proprietary blend of ingredients for the quick and natural relief of insomnia.

The second, longer term objective is to establish a leadership position in the highly fragmented OTC natural and alternative health remedy market by introducing a new kind of product line. By applying hard science to natural products, PuraMed believes it can deliver products providing better performance while having fewer side effects.

The company also believes their products will benefit from the kind of effective opportunity identification and marketing that is largely absent in the natural OTC market. Promising research in the field often goes overlooked for years by large pharmaceutical companies. Through the effective use of clinical trials in conjunction with carefully timed and aggressive marketing, PuraMed is convinced that it can better reach a major part of the OTC market.

The two founders of PuraMed, Russ Mitchell and Jim Higgins, both have extensive experience in the successful sale and distribution of new health products, with novel strategies that have proven highly effective over multiple applications. Through the use of outside production and other third party resources, they plan to rapidly build their position, and consider marketing to be key to the new company’s success.

Let us hear your thoughts below:

Puramed Bioscience Inc. (PMBS.OB) ‏is “One to Watch”

Thursday, April 2nd, 2009

PuraMed Bioscience, Inc. is a pharmaceutical company engaged in the development and marketing of a line of new, non-prescription medicines. These target major consumer health needs including the treatment of headaches, insomnia, and general pain. Trading on the OTCBB, the Company has their corporate headquarters in Schofield, Wisconsin.

PuraMed Bioscience is working to build a profitable business on two opportunities, beginning with three products developed by their founders: LipiGesic M™ for acute relief of migraine headache; LipiGesic H™ for acute relief of tension headaches; and LipiGesic PM™ for insomnia. The Company believes each of these products addresses a very large OTC consumer market.

The Company’s second opportunity is to establish a leadership position in the highly fragmented OTC alternative health remedy market. This is their longer-term opportunity. They are working towards this goal by introducing a “new kind of product line.” Their product line will consist of ‘alternative’ remedies for common ailments, marketed to the masses. By applying hard science to ‘natural’ products, they believe they can offer a line where each product delivers premier performance, all with fewer side effects.

PuraMed BioScience intends to operate their business by applying a comprehensive strategy. This includes identifying effective products with large market opportunities, and employing a unique and effective delivery system. They also plan to perform clinical trials to obtain clinical results to overcome consumer skepticism, as well as employ a direct response sales campaign to refine their message to consumers and generate initial revenue. In addition, the Company is working to achieve broad retail distribution to provide easy consumer access.

Let us hear your thoughts: Puramed Bioscience Inc. Message Board